Use of testosterone in men infected with human immunodeficiency virus in the veterans healthcare system

References

• Anderson, G. M., & Lexchin, J. (1996). Strategies for improving prescribing practice. Canadian Medical Association Journal, 154, 1013–1017.
   PubMed Web of Science ®Google Scholar
• Arver, S., Sinha-Hikim, I., Beall, G., Guerrero, M., Shen, R., & Bhasin, S. (1999). Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. Journal of Andrology, 20(5), 611–618.
   PubMedGoogle Scholar
• Ashby, J., Goldmeier, D., & Sadeghi-Nejad, H. (2014). Hypogonadism in human immunodeficiency virus-positive men. Korean Journal of Urology, 55(1), 9–16. doi: 10.4111/kju.2014.55.1.9
   PubMedGoogle Scholar
• Basaria, S., Coviello, A. D., Travison, T. G. (2010). Adverse events associated with testosterone administration. New England Journal of Medicine, 363(2), 109–122. doi: 10.1056/NEJMoa1000485
   PubMed Web of Science ®Google Scholar
• Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., … Endocrine Society. (2010). Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 95(6), 2536–2559. doi: 10.1210/jc.2009-2354
   PubMed Web of Science ®Google Scholar
• Bhatia, R., Murphy, A. B., Raper, J. L., Chamie, G., Kitahata, M. M., Drozd, D. R., … Network of Integrated Clinical Systems (CNICS). (2015). Testosterone replacement therapy among HIV-infected men in the CFAR network of integrated clinical systems. AIDS, 29(1), 77–81. doi: 10.1097/QAD.0000000000000521
   PubMed Web of Science ®Google Scholar
• Budoff, M. J., Ellenberg, S. S., Lewis, C. E. (2017). Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA, 317(7), 708–716. doi: 10.1001/jama.2016.21043
   PubMed Web of Science ®Google Scholar
• De Gaetano Donati, K., Cauda, R., & Iacoviello, L. (2010). HIV infection, antiretroviral therapy and cardiovascular risk. Mediterranean Journal of Hematology and Infectious Diseases, 2(3), e2010034. doi: 10.4084/mjhid.2010.034
   PubMedGoogle Scholar
• Dobs, A. S., Dempsey, M. A., Landeson, P. W., & Bolk, P. F. (1988). Endocrine disorders in men infected with human immunodeficiency virus. The American Journal of Medicine, 84, 611–616. doi: 10.1016/0002-9343(88)90144-1
   PubMed Web of Science ®Google Scholar
• Gomes, A. C., Aragüés, J. M., Guerra, S., Fernandes, J., & Mascarenhas, M. R. (2017). Hypogonadotropic hypogonadism in human immunodeficiency virus-infected men: Uncommonly low testosterone levels. Endocrinology, Diabetes & Metabolism Case Reports, 17-0104. doi: 10.1530/EDM-17-0104
   PubMedGoogle Scholar
• Grinspoon, S., Corcoran, C., Lee, K. (1996). Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. The Journal of Clinical Endocrinology and Metabolism, 81, 4051–4058.
   PubMed Web of Science ®Google Scholar
• Jasuja, G. K., Bhasin, S., Reisman, J. I., & Rose, A. J. (2015). Ascertainment of testosterone prescribing practices in the VA. Medical Care, 53(9), 746–752. doi: 10.1097/MLR.0000000000000398
   PubMed Web of Science ®Google Scholar
• Jasuja, G. K., Bhasin, S., & Rose, A. J. (2017a). Patterns of testosterone prescription overuse. Current Opinion in Endocrinology, Diabetes and Obesity. doi: 10.1097/MED.0000000000000336
   PubMed Web of Science ®Google Scholar
• Jasuja, G. K., Bhasin, S., Rose, A. J., Reisman, J. I., Hanlon, J. T., Miller, D. R., … Berlowitz, D. R. (2017b). Provider and site-level determinants of testosterone prescribing in the veterans healthcare system. The Journal of Clinical Endocrinology & Metabolism, 102(9), 3226–3233. doi: 10.1210/jc.2017-00468
   PubMed Web of Science ®Google Scholar
• Monroe, A. K., Dobs, A. S., Palella, F. J., Kingsley, L. A., Witt, M. D., & Brown, T. T. (2014). Morning free and total testosterone in HIV-infected men: Implications for the assessment of hypogonadism. AIDS Research and Therapy, 11, 6. doi: 10.1186/1742-6405-11-6
   PubMed Web of Science ®Google Scholar
• Morgan, S. G., Cunningham, C. M., & Hanley, G. E. (2010). Individual and contextual determinants of regional variation in prescription drug use: An analysis of administrative data from British Columbia. PLoS One, 5(12), e15883. doi: 10.1371/journal.pone.0015883
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. (2017, June 1). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Retrieved from http://aidsinfo.nih.gov/Contentfiles/lvguidelines/AdultandAdolescentGL.pdf
   Google Scholar
• Petoumenos, K., Huang, R., Hoy, J. (2017, September 8). Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian positive & peers longevity evaluation study (APPLES). PLoS One, 12(9), e0184583. doi:10.1371/journal.pone.0184583 eCollection 2017 doi: 10.1371/journal.pone.0184583
   PubMed Web of Science ®Google Scholar
• Post, W. S., Budoff, M., Kingsley, L. (2014). Associations between HIV infection and subclinical coronary atherosclerosis: The multicenter AIDS cohort study (MACS). Annals of Internal Medicine, 160(7), 458–467. doi: 10.7326/M13-1754
   PubMed Web of Science ®Google Scholar
• Purcell, D. W., Wolitski, R. J., Hoff, C. C., Parsons, J. T., Woods, W. J., & Halkitis, P. N. (2005). Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS, 19(Suppl 1), S57–S66. doi: 10.1097/01.aids.0000167352.08127.76
   PubMed Web of Science ®Google Scholar
• Rochira, V., Diazzi, C., Santi, D. (2015). Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: A retrospective study. Andrology, 3, 298–308. doi: 10.1111/andr.310
   PubMed Web of Science ®Google Scholar
• Rochira, V., & Guaraldi, G. (2014). Hypogonadism in the HIV-infected man. Endocrinology and Metabolism Clinics of North America, 43(3), 709–730. doi: 10.1016/j.ecl.2014.06.005
   PubMed Web of Science ®Google Scholar
• Rochira, V., Zirilli, L., Orlando, G. (2011). Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One, 6, e28512. doi: 10.1371/journal.pone.0028512
   PubMed Web of Science ®Google Scholar
• Tavernise, S. (2014). FDA panel backs limits on testosterone drugs. New York: The New York Times Company. Retrieved from http://nyti.ms/1uU2VZ1
   Google Scholar
• Triant, V. A. (2013). Cardiovascular disease and HIV infection. Current HIV/AIDS Reports, 10(3), 199–206. doi: 10.1007/s11904-013-0168-6
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. (2014, June 1). FDA adding general warning to testosterone products about potential for venous blood clots. U.S Department of Health and Human Services. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm401746.htm
   Google Scholar
• U.S. Food and Drug Administration. (2016, June 1). FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. U.S Department of Health and Human Services. Retrieved from https://www.fda.gov/drugs/drugsafety/ucm436259.htm
   Google Scholar
• Vigen, R., O’Donnell, C. I., Barón, A. E. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310(17), 1829–1836. doi: 10.1001/jama.2013.280386
   PubMed Web of Science ®Google Scholar
• Wagner, E. H., Austin, B. T., & Von Korff, M. (1996). Organizing care for patients with chronic illness. The Milbank Quarterly, 74, 511–544. doi: 10.2307/3350391
   PubMed Web of Science ®Google Scholar
• Wunder, D. M., Bersinger, N. A., Fux, C. A., Mueller, N. J., Hirschel, B., Cavassini, M., … Swiss HIV Cohort Study. (2007). Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antiviral Therapy, 12(2), 261–265.
   PubMed Web of Science ®Google Scholar